Introduction of MASLD

A transformative paradigm shift occurred in recent years, aiming for a more comprehensive understanding of steatotic liver disease (SLD). In 2023, metabolic dysfunction-associated steatotic liver disease (MASLD) was introduced, recognizing the metabolic aspect of SLD and removing associated stigma. This evolution marks a substantive breakthrough, providing a clearer and more inclusive framework for the diagnosis and management of this prevalent liver disorder. The transition from NAFLD (non-alcoholic fatty liver disease) to MASLD reflects the dynamic nature of medical terminology, emphasizing a more patient-centric approach, and lays the foundation for future strides in diagnosis and treatment. The subsequent sections delve into the historical evolution of liver disease terminology, the transition to MASLD, and an understanding of their clinical spectrum and diagnostic criteria, addressing the intricacies of SLD.